Skip to main content
REGN
NASDAQ Life Sciences

雷金诺（Regeneron）授权的肥胖药奥拉托肽（Olatorepatide）在中国阳性第三期试验中实现高达19%的体重减轻

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$741.98
Mkt Cap
$80.319B
52W Low
$476.487
52W High
$821.11
Market data snapshot near publication time

summarizeSummary

雷金诺（Regeneron）宣布了奥拉托肽（一种双GLP-1/GIP受体激动剂，由该公司授权）的第三期试验在中国患者中的阳性顶线结果。该药物表现出显著的疗效，参与者在第48周实现了高达19%的平均体重减轻，并且与其他双 incretin 试验相比，表现出更有利的胃肠道耐受性特征。该阳性临床更新是在欧洲药品管理局最近对另一雷金诺产品给出阳性意见之后，这为人们对公司最近的10-K中提到的管道监管延迟的普遍担忧提供了有力的反驳。这些强劲的结果使奥拉托肽成为肥胖高价值市场中的一种潜在竞争对手，雷金诺在大中国地区以外拥有其独家开发和商业权。该公司计划在今年晚些时候启动其全球第三期注册计划，投资者将密切关注其进展和进一步的数据展示。

在该公告发布时，REGN的交易价格为$741.98，交易所为NASDAQ，所属行业为Life Sciences，市值约为$803.2亿。 52周交易区间为$476.49至$821.11。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed REGN - Latest Insights

REGN
Apr 29, 2026, 6:54 AM EDT
Filing Type: 10-Q
Importance Score:
8
Regeneron Reports Mixed Q1 Results, Authorizes $3B Buyback, Details Government Pricing Deals & Key Legal Updates
Sentiment: Neutral
View Wiseek Article
REGN
Apr 29, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement
Sentiment: Positive
View Wiseek Article
REGN
Apr 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron Posts 19% Revenue Growth in Q1, Non-GAAP EPS Up 15% Amidst GAAP Decline
Sentiment: Positive
View Wiseek Article
REGN
Apr 24, 2026, 12:25 AM EDT
Source: dpa-AFX
Importance Score:
8
Regeneron's Otarmeni Gene Therapy Approved by FDA for Genetic Hearing Loss
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
FDA Approves Regeneron's Gene Therapy for Inherited Deafness
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 1:30 AM EDT
Source: Reuters
Importance Score:
7
Dupixent Sales Soar 30.8%, Beating Estimates in Sanofi's Q1 Report
Sentiment: Positive
View Wiseek Article
REGN
Apr 22, 2026, 5:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Gains U.S. Approval for Young Children with Chronic Spontaneous Urticaria
Sentiment: Positive
View Wiseek Article
REGN
Apr 21, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron's Cemdisiran Phase 3 Data Published, Regulatory Filing Submitted for gMG
Sentiment: Positive
View Wiseek Article
REGN
Apr 13, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Secures EU Approval for Young Children with Chronic Urticaria, Expanding Key Market
Sentiment: Positive
View Wiseek Article
REGN
Apr 12, 2026, 7:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Regeneron Forms Radiopharma Partnership with Telix, Potentially Worth Over $2.1 Billion
Sentiment: Positive
View Wiseek Article